自去年年底以来，为了适应瞬息万变的市场环境，公司不断推动神经介入业务向差异化治疗类器械聚焦的升级。取栓支架及抽吸导管，扩张球囊及栓塞保护系统，以及弹簧圈等神经介入治疗类器械贡献了35.6%的销售收入，收益为4580万元。神经介入通路器械及其他产品的销售额同比增长42.1%至8270万元。Xinwei Medical -B (06609) released the interim performance for the six months ending June 30, 2024. The group's revenue during this period was 0.128 billion yuan (RMB), a year-on-year increase of 17.24%; gross profit was 82.281 million yuan, a year-on-year increase of 3.22%; and research and development costs were 31.752 million yuan.
Since the end of last year, in order to adapt to the rapidly changing market environment, the company has been continuously promoting the upgrading of its neuro-intervention business to focus on differentiated treatment-related medical devices. Neuro-intervention treatment-related medical devices, such as thrombectomy stents and suction catheters, dilation balloons and embolic protection systems, and spring coils, contributed 35.6% of the sales revenue, amounting to 45.8 million yuan. Sales of neuro-intervention access devices and other products increased by 42.1% to 82.7 million yuan compared to the previous year.
According to the announcement, the increase in revenue is mainly attributed to the continuous growth in sales of thrombectomy devices for acute ischemic stroke (AIS), as well as intracranial arterial stenosis treatment devices and innovative access devices. At the same time, the approval of multiple product registrations by the local drug regulatory authorities has boosted overseas revenue.
During the reporting period, the company's research and development costs amounted to 31.8 million yuan, which were used to support the diversification of neuro-intervention treatment-related medical devices in research and development projects. In the next 18 months, the company expects to launch at least five major neuro-intervention treatment-related medical devices, including intracranial drug-eluting balloon catheters for stenosis treatment (NMPA innovative device qualification), self-expanding drug-coated stents and carotid artery stents, embolic auxiliary stents for hemorrhagic stroke treatment (NMPA innovative device qualification), and blood flow-guided devices. At the same time, the company will enhance the competitiveness of key thrombectomy products (suction catheters and thrombectomy stents) and one-stop medical device solutions to meet the growing demand for stroke treatment in the Chinese market, given the aging population.
During the reporting period, the company's research and development costs amounted to 31.8 million yuan, which were used to support the diversification of neuro-intervention treatment-related medical devices in research and development projects. In the next 18 months, the company expects to launch at least five major neuro-intervention treatment-related medical devices, including intracranial drug-eluting balloon catheters for stenosis treatment (NMPA innovative device qualification), self-expanding drug-coated stents and carotid artery stents, embolic auxiliary stents for hemorrhagic stroke treatment (NMPA innovative device qualification), and blood flow-guided devices. At the same time, the company will enhance the competitiveness of key thrombectomy products (suction catheters and thrombectomy stents) and one-stop medical device solutions to meet the growing demand for stroke treatment in the Chinese market, given the aging population.
